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Prognostic Value and Echocardiographic Determinants
of Plasma Myeloperoxidase Levels in Chronic Heart Failure
W. H. Wilson Tang, MD, FACC,* Wilson Tong, MSC,* Richard W. Troughton, MBBS,†
Maureen G. Martin, RDCS,* Kevin Shrestha, AB,* Allen Borowski, RDCS,* Sue Jasper, BSN,*
Stanley L. Hazen, MD, PHD, FACC,* Allan L. Klein, MD, FACC*
Cleveland, Ohio; and Christchurch, New Zealand
Objectives The purpose of this study was to explore the relationship between myeloperoxidase (MPO) and cardiac structure,
performance, and prognosis.
Background Myeloperoxidase is an inflammatory marker that is elevated in patients with heart failure (HF) and cardiac dys-
function, with mechanistic links to plaque vulnerability and left ventricular (LV) remodeling.
Methods We evaluated plasma MPO levels (CardioMPO, PrognostiX, Inc., Cleveland, Ohio) in 140 patients with chronic
systolic HF (LV ejection fraction 35%) and examined the plasma MPO levels’ relationships with echocardio-
graphic indexes of systolic and diastolic performance, as well as long-term clinical outcomes (death, cardiac
transplantation, or HF hospitalization).
Results Within the overall cohort, increasing plasma MPO levels were associated with increasing likelihood of more ad-
vanced HF (restrictive diastolic stage, right ventricular systolic dysfunction 3, and tricuspid regurgitation
area 1.8 cm2). Plasma MPO levels were predictive of long-term clinical outcomes (risk ratio [95% confidence
interval]  3.35 [1.52 to 8.86]), even after adjustment for age, LV ejection fraction, plasma B-type natriuretic
peptide (BNP), creatinine clearance, or diastolic stage. In receiver-operator characteristic curve analyses, addi-
tion of MPO to BNP testing augmented the predictive accuracy of future adverse clinical events (area under the
curve 0.66 for BNP only [chi-square test  12.9, p  0.0003], and 0.70 for BNP plus MPO [chi-square test 
15.87, p  0.0004]).
Conclusions In chronic systolic HF, elevated plasma MPO levels are associated with an increased likelihood of more ad-
vanced HF. Moreover, elevated plasma MPO levels within a HF subject seem to be predictive of increased ad-
verse clinical outcomes. (J Am Coll Cardiol 2007;49:2364–70) © 2007 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.053c
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sncreasing data support a role for inflammation and oxida-
ive stress in the pathophysiology of heart failure (HF) (1).
here is a strong association between increased lipid per-
xidation (plasma and urine F2 isoprostane levels), de-
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Manuscript received October 17, 2006; revised manuscript received February 7,
007, accepted February 8, 2007.reased antioxidant levels, and increased severity of HF
2,3). Endothelial dysfunction as a result of oxidative stress
s associated with an increased mortality risk in patients with
oth ischemic and nonischemic HF (4).
Myeloperoxidase (MPO) is a leukocyte-derived enzyme
hat can produce a cascade of reactive oxidative species,
ncluding hypochlorous acid and other reactive oxidant
pecies, which may ultimately lead to lipid peroxidation,
irect scavenging of nitric oxide, and nitric oxide synthase
nhibition (5). Recent studies suggest that plasma MPO
evels are elevated in patients with chronic systolic HF (6),
nd elevated MPO levels provide good diagnostic value in
ommunity-based screening for cardiac dysfunction (7). In
nimal studies, preservation of left ventricular (LV) function
as been observed in both a coronary artery ligation model (8)
nd an ischemia reperfusion model in MPO null mice (9),
uggesting that MPO may provide a mechanistic link between
nflammation, oxidant stress, and impaired cardiac remodeling.
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June 19, 2007:2364–70 Myeloperoxidase in Heart Failure PrognosisThe primary objective of this study was to determine the
elationship between plasma MPO levels and cardiac struc-
ure, systolic and diastolic performance, and overall prognosis
n patients with chronic systolic HF. We hypothesized that
levated levels of MPO might be observed across varying stages
f cardiac dysfunction and may be predictive of long-term
linical outcomes.
ethods
tudy design and population. The neurohormonal sub-
tudy of the ADEPT (Assessment of Doppler Echocardi-
graphy in Prognosis and Therapy) study has been previ-
usly described (10), and was approved by the Cleveland
linic Institutional Review Board. After informed consent,
40 ambulatory patients with stable, chronic systolic HF
LV ejection fraction [LVEF] 35%, New York Heart
ssociation functional class II to IV) underwent echocar-
iographic evaluation of systolic and diastolic performance
s well as plasma sample collection. Clinical events (all-
ause mortality, cardiac transplantation, or HF hospitaliza-
ion) were prospectively tracked by scheduled telephone
ollow-up and validated by chart review as previously de-
cribed (11). Creatinine clearance was calculated using the
ockcroft-Gault equation based on creatinine, age, and
eight. Plasma B-type natriuretic peptide (BNP) levels
ere analyzed by the Christchurch BNP assay as published
reviously (10), which is a well-validated radioimmunoassay
ith the normal range (up to the 97.5th percentile of
ormal patients) to be 40 pg/ml and values slightly lower
han that of commercially available assays (12).
lasma MPO assays. All samples were collected using
thylenediaminetetraacetic acid plasma tubes, processed and
rozen at 80°C until analyzed. Plasma MPO levels were
etermined by the CardioMPO II test (PrognostiX, Inc,
leveland, Ohio), cleared by the U.S. Food and Drug
dministration. This sandwich enzyme-linked immunosor-
ent assay showed a minimum detection limit (as calculated
y interpolation of the mean plus 2 SDs) of 30 pM, with a
ithin-run precision of 4.8%. For apparently healthy
iddle-aged patients, we have previously reported mean
lasma MPO levels of 204  139 pM. Accuracy studies
sing method of standard additions with isolated pure
uman MPO and multiple (n 20) plasma samples showed
verall recovery of 97.8 2.7%. All laboratory analyses were
erformed with investigators blinded to clinical outcomes.
ransthoracic echocardiography. Comprehensive trans-
horacic echocardiography was performed using commercially
vailable HDI 5000 (Phillips Medical Systems, Bothell,
ashington) and Acuson Sequoia (Siemens Medical Solu-
ions USA Inc., Malvern, Pennsylvania) machines. Two-
imensional and color Doppler imaging was performed in
tandard parasternal and apical views. Diastolic indexes
including pulse-wave Doppler, color M-mode, and tissue
oppler imaging) were acquired over 10 consecutive beatssing sweep speeds of 50 cm/s and 100 cm/s using previ- vusly described techniques. Clas-
ification of diastolic stage was
etermined as follows: Stage I
impaired relaxation) consists of
itral E/A 1, deceleration
ime 220 ms, pulmonary vein
/D 1, atrial reversal (AR)
35 cm/s; Stage II (pseudonor-
al) shows mitral E/A  1 to 2,
ulmonary vein S/D 1, decel-
ration time 220 ms, AR 35
m/s; Stage III (restrictive) gives
itral E/A 2, pulmonary vein S/D 1, deceleration time
150 ms, AR 35 cm/s. Estimates for left atrial pressure
ere determined from pulmonary vein S/D, E/septal Ea,
nd mitral E/Vp ratios. The LVEF and cardiac volumes
ere measured using the Simpson biplane method.
easurements were averaged over 3 cycles (5 cycles for
trial fibrillation), and 2 experienced individuals who
ere blinded from the neurohormonal data made all mea-
urements.
tatistical analysis. Plasma MPO levels were non-
ormally distributed and were treated as nonparametric
ariables (expressed as median and interquartile range
IQR]). Analysis of variance or the Kruskal-Wallis test was
sed to assess differences in continuous clinical variables
cross MPO tertiles according to whether or not the
istribution was normal, whereas contingency table analysis
as performed to assess differences in clinical proportions
cross MPO tertiles. Normality was assessed by the
hapiro-Wilk W test. Systolic blood pressure, creatinine
learance, BNP, LV end-diastolic volume index, and LVEF
ere non-normally distributed, and age and heart rate were
ormally distributed. The Spearman rank correlation
ethod was used as a nonparametric measure of association
or correlations between plasma MPO levels and all clinical
ariables. The odds ratios of having altered systolic or
iastolic performances were calculated from multivariate
ogistic regression across 1st, 2nd, and 3rd tertiles of MPO
ith respect to the 1st tertile (odds ratio  1.0). Adjust-
ents were made for age and BNP levels. Kaplan-Meier
urvival plots were calculated from baseline to time of
ll-cause mortality, cardiac transplantation, or HF hospital-
zation over a mean follow-up of 33 months. All univariate
nd multivariate Cox proportional hazard analyses were also
alculated with all-cause mortality, cardiac transplantation,
r HF hospitalization as outcome, and with plasma MPO
evels treated as a categorical variable modeling differences
n outcomes for patients within the highest 2 tertiles relative
o the lowest of plasma MPO. Receiver-operator character-
stic curve analysis was performed to determine the incre-
ental prognostic value of MPO with BNP. A p value
0.05 was considered statistically significant. Statistical
nalyses were performed using SAS version 9.1 and JMP
Abbreviations
and Acronyms
BNP  B-type natriuretic
peptide
HF  heart failure
IQR  interquartile range
LV  left ventricular
LVEF  left ventricular
ejection fraction
MPO  myeloperoxidaseersion 5.1 (SAS Institute Inc., Cary, North Carolina).
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Myeloperoxidase in Heart Failure Prognosis June 19, 2007:2364–70esults
n our study cohort, the mean and median plasma MPO
ere 431  337 pM and 303 pM [IQR  256 to 430],
espectively. Table 1 illustrates the patients characteristics
tratified according to plasma MPO tertiles in the overall
ohort. Left ventricular ejection fraction or LV end-
iastolic dimensions, as well as other clinical and laboratory
ata, gave no significant differences across MPO tertiles. In
ontrast, increasing plasma MPO levels were associated
ith a higher proportion of right ventricular systolic dys-
unction. In multivariable stepwise logistic regression anal-
sis using variables that showed statistically significant
orrelation with logarithmic transformed plasma MPO
evels (Table 2), only tissue Doppler imaging-derived septal
a wave showed an independent association with MPO
evels (p  0.01).
The median LVEF level in this study cohort was 26%,
ence further analyses regarding more impaired systolic
ysfunction were stratified according to those at or below
edian LVEF (26% or25%) versus those above median
VEF (25% or 26%). The relationship between plasma
PO levels and echocardiographic measures of LV filling
ressure and compliance (including mitral inflow E/A ratio,
eceleration time, pulmonary vein S/D ratio, and tissue
oppler imaging-derived E/septal Ea ratio) seemed stron-
er in the LVEF 25% cohort compared with that in the
Patient Baseline Characteristics Across Tertiles
Table 1 Patient Baseline Characteristics Ac
Variable 1st Tertile
MPO (pM) 271
Age (yrs) 60
Male gender (%) 72
NYHA functional class III or IV (%) 24
Ischemic etiology (%) 38
Heart rate (beats/min) 74
Systolic blood pressure (mm Hg) 114
Medications (%)
ACE inhibitors and/or ARBs 93
Beta-blockers 57
Loop diuretics 70
Digoxin 59
Spironolactone 22
Nitrates 32
Comorbid conditions
Hypertension (%) 67
Diabetes mellitus (%) 29
Creatinine clearance (ml/min) 77
BNP (pg/ml) 95
Echocardiographic data
LVED volume index (ml/m2) 111
LVEF (%-units) 26
Diastolic stage II (%) 51
RV systolic dysfunction class 3 (%) 13
Mitral regurgitation 3 (%) 4
*p  0.05.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor bl
end-diastolic; LVEF  left ventricular ejection fraction; MPO  myeloperoxidaVEF 25% cohort (Table 2). In further examination of
his relationship in patients with LVEF 20%, the corre-
ation with MPO became even stronger, particularly for
itral E/A ratio (r 0.56, p 0.007), pulmonary vein S/D
atio (r0.57, p 0.005), tissue Doppler imaging septal
a (r  0.53, p  0.014), and diastolic stage (r  0.49,
 0.021). In the total population, the likelihood of
etecting more advanced diastolic (diastolic stage III) or
ight ventricular systolic dysfunction was higher with in-
reasing tertiles of plasma MPO levels. A significantly
igher percentage of patients with diastolic stage III (45%
s. 24%, p  0.048) or RV systolic dysfunction 3 (38%
s. 13%, p  0.006) were in the 3rd MPO tertile compared
ith those in the 1st MPO tertile (Table 3).
After a mean follow-up of 33  16 months, 23% of
atients experienced death or cardiac transplantation,
hereas 29% of patients had combined end points of death,
ransplantation, or HF hospitalization. Compared with
hose without clinical events, patients who died or under-
ent heart transplantation (median [IQR] in pM, 345 [283
o 481] vs. 290 [247 to 425], p  0.035) and those with
ombined end points of death, transplantation, or HF
ospitalization (median [IQR] in pM, 360 [284 to 452] vs.
89 [247 to 418], p  0.013) had higher plasma MPO
evels. Increasing tertiles of MPO were predictive of mor-
ality and cardiac transplantation alone in the study cohort
lasma MPO Levels
Tertiles of Plasma MPO Levels
6) 2nd Tertile (n  47) 3rd Tertile (n  47)
271–385 385
55 13 57 15
79 81
38 36
45 40
76 16 74 14
113 20 108 19
89 91
64 57
87 74
71 52
35 26
28 26
53 51
23 37
90 32 89 45
110 105 117 131
106 47 111 38
26 6 25 5
66 68
23* 38*
6 17of P
ross
(n  4
12
14
20
37
96
32
7
*ocker; BNP  B-type natriuretic peptide; LVED  left ventricular
se; NYHA  New York Heart Association; RV  right ventricular.
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June 19, 2007:2364–70 Myeloperoxidase in Heart Failure Prognosisrisk ratio  1.56 [95% confidence interval 1.01 to 2.46],
 0.043). Figure 1A illustrates the long-term adverse
linical events (death, cardiac transplantation, or HF hos-
italization) of patients with chronic systolic HF stratified
y tertiles of plasma MPO levels, whereas Figure 1B
ompares patients within the highest 2 plasma MPO tertiles
271 pM) relative to the lowest with each subgroup
urther stratified by median plasma BNP (65 pg/ml).
atients with plasma MPO levels within the upper 2
ertiles and above-median plasma BNP fared significantly
orse than those with lower plasma MPO and BNP
evels (Fig. 1B).
In further receiver-operator characteristic curve analysis,
dding MPO to BNP testing augmented the predictive
ccuracy of future adverse clinical events (area under the
urve increased from 0.66 for BNP only [chi-square 12.9,
 0.0003] to 0.70 for BNP plus MPO [chi-square 
5.87, p  0.0004]). After individual adjustments with age,
Correlation Between Plasma MPO Levels and Clinharac eristics for the Total Study Population and
Table 2 Correlation Between Plasma MPO LevCharacteristics for the Total Study Po
Variable
Overall C
Spearman Correlatio
Age (yrs) 0.01
Heart rate (beats/min) 0.01
BNP (pg/ml) 0.13
NT-proANP (nM) 0.10
Creatinine clearance (ml/min) 0.01
LVED volume index (ml/m2) 0.06
LVEF (%) 0.13
Mitral peak E/A ratio 0.14
Transmitral DT (ms) 0.10
Pulmonary vein S/D ratio 0.19
TDI septal systolic (cm/s) 0.06
TDI septal Ea (cm/s) 0.07
TDI septal Aa (cm/s) 0.21
E/septal Ea ratio 0.16
CMM Vp (cm/s) 0.01
E/Vp 0.06
Mitral regurgitation severity 0.07
Diastolic stage 0.18
RV systolic dysfunction class 0.20
CMM  color M-mode; DT  deceleration time; NS  not significant;
imaging; other abbreviations as in Table 1.
Odds Ratios and 95% Confidence Intervals for thPresence f Clinical Conditions Across Increasin
Table 3 Odds Ratios and 95% Confidence InPresence of Clinical Conditions Acr
Clinical Condition 1st Tertile (n
Diastolic stage III 1.0
LVEF 25% 1.0
Diastolic stage III plus LVEF 25%
Unadjusted 1.0
Adjusted (age and BNP) 1.0
RV systolic dysfunction class 3 1.0
Tricuspid regurgitation area 1.8 cm2 1.0First MPO tertile271 pM, second MPO tertile 271 to 385 pM, third MPO te
Abbreviations as in Table 1.VEF, New York Heart Association functional class, or
lasma BNP levels, increasing MPO remained a significant
redictor of long-term clinical events (Table 4). Also,
igher MPO levels are associated with a worse prognosis
hen combined adjustments include LVEF, plasma BNP,
nd diastolic stage (risk ratio [95% confidence interval] 
.52 [1.06 to 7.43], p  0.036). In addition, a poorer
rognosis was shown in patients with elevated plasma MPO
evels (above 1st tertile) and LVEF 25% or restrictive LV
iastolic filing pattern (Fig. 2). Stratifying plasma MPO by
edian levels rather than tertiles yielded similar results.
iscussion
uring inflammation, MPO is released, for which its
easurement in systemic circulation may be used as an
ndex of leukocyte activation and oxidant stress. The MPO
evels correlate with cardiovascular events in patients pre-
nd Echocardiographice Patient Coh rt With LVEF <25%
nd Clinical and Echocardiographic
ion and in the Patient Cohort With LVEF <25%
LVEF <25% Subgroup
p Value Spearman Correlation p Value
NS 0.05 NS
NS 0.04 NS
NS 0.16 NS
NS 0.24 NS
NS 0.08 NS
NS 0.05 NS
NS 0.05 NS
NS 0.34 0.008
NS 0.36 0.007
0.026 0.41 0.001
NS 0.09 NS
NS 0.04 NS
0.017 0.30 0.021
NS 0.28 0.030
NS 0.15 NS
NS 0.19 NS
NS 0.09 NS
0.045 0.38 0.002
0.017 0.25 0.048
NP  N-terminal pro-atrial natriuretic peptide; TDI  tissue Doppler
yeloperoxidase Tertiles
ls for the
ncreasing Myeloperoxidase Tertiles
) 2nd Tertile (n  47) 3rd Tertile (n  47)
2.2 (0.8–5.8) 2.6 (1.0–7.0)*
1.7 (0.7–4.2) 1.6 (0.7–3.8)
3.5 (1.1–13.3)* 4.3 (1.4–16.3)*
3.9 (0.9–21.5) 6.9 (1.5–47.5)*
2.0 (0.7–6.3) 4.0 (1.5–12.3)†
2.4 (0.9–6.2) 3.7 (1.5–9.6)†ical ain th
els a
pulat
ohort
neg M
terva
oss I
 46rtile385 pM. *p 0.05. †p 0.01.
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Myeloperoxidase in Heart Failure Prognosis June 19, 2007:2364–70enting with chest pain (13) and in patients with end-stage
enal diseases (14). We previously have reported the rela-
ionship between increasing plasma MPO levels and the
resence of HF in the general population (15). Recent
tudies by Ng et al. (7) also report a potential role for initial
lasma MPO testing (followed by plasma BNP and high-
ensitivity C-reactive protein testing) for improved sensitiv-
ty in population screening for occult LV systolic dysfunc-
ion among apparently healthy patients. The present studies
xtend these initial reports, suggesting that plasma MPO
evels are higher in patients with more advanced HF as
etermined by detailed echocardiographic examination in-
luding LV diastolic function and right ventricular systolic
Figure 1 Kaplan-Meier Analysis of All-Cause Death, Cardiac
Transplantation, or Heart Failure Hospitalization
/MPO  first tertile (271 pM) versus second and third tertile (271 pM)
plasma MPO levels; /BNP  below-median versus above-median plasma
BNP levels (median  65 pg/ml). BNP  B-type natriuretic peptide; MPO 
myeloperoxidase.ysfunction, and may provide prognostic values in predict-
‡ng long-term clinical outcomes, even after adjusting for
ommonly used prognostic variables.
Recently from a post hoc analysis of the SOLVD (Studies
f Left Ventricular Dysfunction) study, subclinical inflam-
ation, as indicated by an increase in serial total leukocyte
ount and neutrophil counts, has been associated with
orsening HF outcomes (16). These results also were
onsistent with a recent pilot study showing that increases in
eutrophil count during follow-up were associated with
udden unexpected death (17). It is conceivable that chronic
eukocyte activation may lead to disease progression of HF,
lthough direct evidence is somewhat limited and largely in
nimal models (18,19). Our data provide a direct mecha-
istic link between leukocyte-driven inflammation, degree
f severity of altered cardiac structure and performance, and
linical outcomes in humans. It is likely that the combina-
ion of progressive ventricular degradation and failed coun-
erregulatory antioxidant mechanisms may contribute to
levated oxidative stress in severe left and right ventricular
ystolic and diastolic dysfunction.
Within the overall cohort, increasing plasma MPO levels
ere associated with an increasing likelihood of more
estrictive (Stage III) diastolic dysfunction and more severe
3) right ventricular systolic dysfunction. This is con-
istent with animal studies showing the association of
levated MPO levels with collagen accumulation in matrix
emodeling after myocardial infarction (20). Overactivation
nivariate and Multivariate Cox Proportionalazard Analyses of Death, Cardiac Transpl ntation,r HF Hospitalization Across MPO Tertiles
Table 4
Univariate and Multivariate Cox Proportional
Hazard Analyses of Death, Cardiac Transplantation,
or HF Hospitalization Across MPO Tertiles
Variable
Hazard Ratio
(95% Confidence Interval) p Value
Log10 MPO (41 events)* 3.35 (1.52–8.86) 0.002
Adjusted for age (yrs) 3.38 (1.52–8.95) 0.002
Adjusted for LVEF (%) 2.94 (1.33–7.79) 0.006
Adjusted for NYHA functional
class
2.97 (1.35–7.86) 0.006
Adjusted for log10 BNP 3.45 (1.47–10.07) 0.003
Adjusted for creatinine
clearance (ml/min)
3.56 (1.51–10.42) 0.002
Adjusted for diastolic stage 2.37 (1.06–6.31) 0.034
Adjusted for RV systolic
dysfunction class
2.85 (1.28–7.55) 0.009
Adjusted for tricuspid
regurgitation area (cm2)
2.96 (1.21–8.84) 0.016
Multivariable model (37 events)
Log10 MPO* 2.92 (1.24–8.54) 0.012
Log10 BNP† 1.71 (1.14–2.63) 0.010
LVEF (%)† 0.81 (0.55–1.18) NS
Multivariable model (37 events)
Log10 MPO* 2.52 (1.06–7.43) 0.036
Log10 BNP† 1.52 (0.97–2.42) NS
LVEF (%)† 0.85 (0.57–1.25) NS
Diastolic stage‡ 1.37 (0.87–2.23) NS
Hazard ratios for patients with values in the highest 2 tertiles (271 pM) relative to the lowest
ertile. †Hazard ratios per 1-SD increment (1 SD for log10 BNP  0.48; 1 SD for LVEF  5.93%).
Hazard ratios per 1 increment.
Abbreviations as in Table 1.
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June 19, 2007:2364–70 Myeloperoxidase in Heart Failure Prognosisf peroxidases and generation of reactive oxygen species also
re implicated in diastolic dysfunction via matrix remodel-
ng in diabetic (21) and doxorubicin-induced (22) cardio-
yopathies. These results thus may offer insight into the
ole of MPO-mediated oxidative stress in the progression of
estrictive filling pattern and myocardial fibrosis.
Previous outcome studies also have shown that other
arkers of oxidative stress, such as oxidized low-density
ipoprotein, catecholamine-induced adrenolutin, and mal-
ndialdehyde from lipid peroxidation, are predictive of
ortality (23–25). However, measurement of these bio-
arkers is technically challenging. Further, these have not
een shown to remain significant independent predictors of
dverse outcomes even after adjustment for either LVEF or
NP levels. In the present study, the prognostic value of
Figure 2 Adverse Event Rate and
Corresponding Hazard Ratios for Subgroups
Hazard ratios are calculated relative to the subgroup with the lowest risk (haz-
ard ratio  1.0). HF  heart failure; LVEF  left ventricular ejection fraction;
MPO  myeloperoxidase.lasma MPO for predicting future adverse clinical events temained significant even after adjustment for both LVEF
nd plasma BNP levels, as well as other traditional cardio-
ascular risks. These observations establish the fact that
lasma MPO, a commercially available immunoassay
leared by the U.S. Food and Drug Administration, may
rovide additive prognostic value heralding more severe
nderlying disease. The present results also possibly provide
nsight into underlying disease mechanisms, including a
otential catalytic source for lipid peroxidation, cytokine
ctivation, apoptosis, and platelet adhesion. These patho-
hysiological processes may be distinct from those leading
o LV systolic dysfunction or BNP production, and there-
ore may identify a unique HF phenotype. Interestingly, the
bility of diastolic and right ventricular systolic performance
o diminish the prognostic value of MPO also implies a
elationship between MPO-derived oxidative stress and
ltered diastolic and right ventricular systolic performance in
he setting of chronic systolic HF. It is unclear why there is
n asymmetric distribution of hazard ratios across tertiles of
PO with respect to associated echocardiographic abnor-
alities (Table 3) and clinical events (Fig. 1). It is conceiv-
ble that the absence of subclinical inflammation and
xidative stress represents the contributing factor to the lack
f disease progression seen in this cohort of patients with
hronic stable HF, and will require larger clinical trials to
alidate these findings.
Recently, several studies have suggested the potential
enefits of statin therapy in patients with chronic HF
ndependent of their lipid-lowering effects (26–29). Al-
hough our study population has a low rate of statin use to
xamine the potential influence of statins on plasma MPO
evels, several multicenter mortality trials currently are
nderway to determine whether statin therapy improves
ardiac performance and reduces morbidity and mortality in
he HF patient population. The proposed underlying mech-
nism is complex, and may involve both enhanced nitric
xide production and reductions in cytokine production,
eactive oxygen species generation, or matrix metallopro-
einase activity (30–32). Shishehbor et al. (33) have shown
he possibility of modulation of nitrosative stress by detect-
ng a significant reduction in serum nitrotyrosine levels in
atients without underlying cardiac dysfunction after statin
herapy. Furthermore, Kumar et al. (34) recently reported
hat MPO expression was suppressed by statins. It is
ntriguing to speculate that in symptomatic patients with
hronic systolic HF and with heightened plasma MPO
evels (as one of the major contributors of nitrosative stress),
tatin therapy may provide beneficial effects via modulation
f these oxidative-nitrosative stress pathways.
There are several limitations to this analysis. It is possible
hat underlying drug therapy may influence plasma MPO
evels (such as beta-adrenergic blocker) even though the
rug utilization rates across MPO tertiles were similar. Our
tudy did not collect information regarding baseline total
eukocyte counts to evaluate their prognostic values relative
o plasma MPO, although prior clinical studies have re-
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ardiac risks even when adjusting for leukocyte count (13).
he relatively low number of clinical events may limit the
bility of multivariable statistical analyses to compare the
rognostic role of MPO. Despite the need to confirm our
ndings in larger clinical studies, the potential ability to
nravel an underlying oxidative stress phenotype of chronic
ystolic HF is promising.
onclusions
igher plasma levels of MPO were associated with an
ncreasing likelihood of greater severity of impairment of
V diastolic performance and right ventricular systolic
ysfunction, and an increasing likelihood of adverse clinical
vents after adjustments for systolic dysfunction.
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